Deceased donor kidney transplants are time-critical, and it is uncommon to attempt them robotically
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
The deal accelerates GE HealthCare’s digital transformation, expanding its reach into outpatient care and enterprise imaging—a $2 billion-plus growth market
Adzynma, approved for both adults and children with cTTP, is a recombinant enzyme therapy designed to replace the deficient ADAMTS13 enzyme
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
The initiative aims to connect startups and tech companies with its business units,
The facility will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies
The issue comprises a fresh issue of Rs. 95 crore and targeting a total raise of around Rs. 895 crore
Subscribe To Our Newsletter & Stay Updated